Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effects of Neuromuscular Electrical Stimulation Combined With Ultrasound on Stroke Patients With Sarcopenia

13. juli 2026 oppdatert av: XuePing Li, Nanjing First Hospital, Nanjing Medical University

A Randomized Controlled Trial of Neuromuscular Electrical Stimulation Combined With Therapeutic Ultrasound on Muscle Mass, Muscle Strength, and Physical Function in Stroke Patients With Sarcopenia.

The goal of this clinical trial is to learn if combining neuromuscular electrical stimulation (NMES) with therapeutic ultrasound (UT) can improve muscle mass, muscle strength, and physical function in stroke patients with sarcopenia.

The main questions it aims to answer are:

Does combined NMES and UT therapy increase muscle mass and strength more than conventional rehabilitation alone?

Does the combined therapy improve physical function (balance, gait, and activities of daily living) better than either therapy alone?

Researchers will compare four groups:

Conventional rehabilitation only (control group)

Conventional rehabilitation plus UT

Conventional rehabilitation plus NMES

Conventional rehabilitation plus combined UT and NMES

Participants will:

Receive 4 weeks of rehabilitation therapy, 6 days per week

Undergo assessments of muscle mass (via ultrasound), muscle strength (handgrip, isokinetic testing), and physical function (Fugl-Meyer, FIM, balance, and gait tests) before and after the 4-week intervention

Receive either UT (1 MHz, 0.5-0.8 W/cm², 20 min/session, 2 sessions/day), NMES (50 Hz, 300μs pulse width, 20 min/session, 2 sessions/day), both, or standard care only

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Detaljert beskrivelse

Background: Stroke is a leading cause of disability worldwide. Sarcopenia, characterized by loss of muscle mass and function, is a common complication after stroke, with a prevalence of approximately 46.7% within the first six months. Post-stroke sarcopenia significantly impairs patients' ability to walk independently, maintain balance, and perform daily activities. Current interventions primarily include exercise, physical therapy, and nutritional support, but these approaches have limitations, particularly for elderly patients who cannot tolerate vigorous exercise due to comorbidities or disability.

Therapeutic ultrasound (UT) is a non-invasive, safe, and cost-effective modality that promotes tissue regeneration and muscle repair through mechanical vibration and increased growth factor secretion. Neuromuscular electrical stimulation (NMES) induces involuntary muscle contraction, preventing disuse atrophy, preserving muscle thickness, and promoting protein synthesis. However, no study has systematically compared UT and NMES, or their combination, specifically in stroke-related sarcopenia.

Objective: This study aims to (1) compare the efficacy of UT versus NMES in improving muscle mass, strength, and physical function in stroke patients with sarcopenia; (2) evaluate whether combined UT and NMES therapy produces synergistic effects superior to either monotherapy; and (3) explore the potential mechanisms of action.

Study Design: This is a prospective, single-center, randomized, single-blind controlled trial. Eligible participants will be randomly assigned in a 1:1:1:1 ratio to one of four groups: (1) conventional rehabilitation alone (control), (2) UT + conventional rehabilitation, (3) NMES + conventional rehabilitation, or (4) combined UT + NMES + conventional rehabilitation. The intervention period is 4 weeks, with assessments performed at baseline and immediately after the intervention.

Sample Size: Based on prior literature (α = 0.05, 1-β = 0.80, effect size = 0.25), accounting for a 10% dropout rate, the total sample size is 152 participants (approximately 38 per group).

Interventions:

Conventional rehabilitation: Exercise therapy (30 min) and occupational therapy (30 min), twice daily, 6 days/week for 4 weeks.

UT group: In addition to conventional rehabilitation, UT (1 MHz, 0.5-0.8 W/cm², 20 min, 2 sessions/day, 6 days/week) applied to the affected wrist extensors and quadriceps.

NMES group: In addition to conventional rehabilitation, NMES (50 Hz, 300μs pulse width, intensity adjusted to visible muscle contraction, 20 min, 2 sessions/day, 6 days/week) applied to the same muscle groups.

Combined group: Both UT and NMES in addition to conventional rehabilitation.

Outcome Measures:

Primary outcomes: Muscle mass (muscle thickness via musculoskeletal ultrasound), muscle strength (handgrip strength, isokinetic torque), and physical function (Fugl-Meyer Assessment, Functional Independence Measure, modified Rankin Scale, balance, and gait tests).

Secondary outcomes: Surface electromyography (RMS and iEMG), Hamilton Depression Scale, and safety/adverse event monitoring.

Statistical Analysis: Data will be analyzed using SPSS 26.0. Intention-to-treat analysis will be applied. Between-group comparisons will use one-way ANOVA with post-hoc tests (LSD/Bonferroni), within-group changes will use paired t-tests, and correlation analyses will explore relationships between muscle mass improvement and functional recovery.

Ethics and Dissemination: The study has been approved by the Ethics Committee of Nanjing First Hospital (Approval Number: KY20250425-12). All participants will provide written informed consent. Results will be disseminated through peer-reviewed publications and conference presentations.

Studietype

Intervensjonell

Registrering (Antatt)

152

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Jiangsu
      • Nanjing, Jiangsu, Kina, 2100061
        • Nanjing First Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Diagnosis of first-ever stroke confirmed by CT or MRI, with stable vital signs, disease course between 3 weeks and 6 months.

Diagnosis of sarcopenia according to the 2019 Asian Working Group for Sarcopenia (AWGS) criteria: reduced handgrip strength (male < 28 kg, female < 18 kg) and/or gait speed < 1.0 m/s, and reduced appendicular skeletal muscle mass index (male < 7.0 kg/m², female < 5.4 kg/m²).

Age between 30 and 75 years.

Brunnstrom stage of affected upper and lower limbs ≥ III, and modified Ashworth scale ≤ 2.

No significant consciousness or cognitive impairment.

Willing and able to provide written informed consent.

Exclusion Criteria:

  • Presence of significant emotional or cognitive impairment.

Obesity or overweight (body mass index > 25 kg/m²).

Unable to stand up from a chair with or without assistance.

Comorbidities including renal, hepatic, or heart failure.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Ingen inngripen: Conventional Rehabilitation Only
Participants receive conventional rehabilitation therapy only, including exercise therapy and occupational therapy, 2 sessions per day, 6 days per week for 4 weeks.
Eksperimentell: Ultrasound Therapy Plus Conventional Rehabilitation
Participants receive conventional rehabilitation therapy plus therapeutic ultrasound (UT) applied to the affected wrist extensors and quadriceps (1 MHz, 0.5-0.8 W/cm², 20 min/session, 2 sessions/day, 6 days/week) for 4 weeks.
Ultrasound therapy delivered at 1 MHz, 0.5-0.8 W/cm², 20 minutes per session, 2 sessions per day, 6 days per week for 4 weeks, using the PHYSIOSON-EXPERT device. Applied to the affected wrist extensors and quadriceps.
Eksperimentell: Neuromuscular Electrical Stimulation Plus Conventional Rehabilitation
Participants receive conventional rehabilitation therapy plus neuromuscular electrical stimulation (NMES) applied to the affected wrist extensors and quadriceps (50 Hz, 300μs pulse width, intensity adjusted to visible muscle contraction, 20 min/session, 2 sessions/day, 6 days/week) for 4 weeks.
Neuromuscular electrical stimulation delivered at 50 Hz, 300μs pulse width, intensity adjusted to visible muscle contraction, 20 minutes per session, 2 sessions per day, 6 days per week for 4 weeks, using the LGT-2320D device. Applied to the affected wrist extensors and quadriceps.
Eksperimentell: Combined UT and NMES Plus Conventional Rehabilitation
Participants receive conventional rehabilitation therapy plus both therapeutic ultrasound (UT) and neuromuscular electrical stimulation (NMES) applied to the affected wrist extensors and quadriceps, using the same parameters as the single-therapy groups, for 4 weeks.
Ultrasound therapy delivered at 1 MHz, 0.5-0.8 W/cm², 20 minutes per session, 2 sessions per day, 6 days per week for 4 weeks, using the PHYSIOSON-EXPERT device. Applied to the affected wrist extensors and quadriceps.
Neuromuscular electrical stimulation delivered at 50 Hz, 300μs pulse width, intensity adjusted to visible muscle contraction, 20 minutes per session, 2 sessions per day, 6 days per week for 4 weeks, using the LGT-2320D device. Applied to the affected wrist extensors and quadriceps.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Quadriceps Muscle Thickness on the Affected Side
Tidsramme: Baseline and 4 weeks
Quadriceps muscle thickness on the affected (paretic) side will be measured using B-mode musculoskeletal ultrasound with a high-frequency linear probe. Muscle thickness includes the thickness of the rectus femoris and vastus intermedius. Measurements will be taken with the participant in the supine position with hips and knees extended.
Baseline and 4 weeks
Change in Handgrip Strength
Tidsramme: Baseline and 4 weeks
Handgrip strength will be measured using a hand dynamometer on the unaffected side. Participants will be asked to squeeze the dynamometer with maximum effort for 3 seconds, and the average of three measurements will be recorded.
Baseline and 4 weeks
Change in Fugl-Meyer Assessment Score
Tidsramme: Baseline and 4 weeks
The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index. It is scored on a 3-point ordinal scale (0=cannot perform, 1=partially performs, 2=performs fully). Total score ranges from 0 to 100, with higher scores indicating better motor function.
Baseline and 4 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Functional Independence Measure (FIM) Score
Tidsramme: Baseline and 4 weeks
The Functional Independence Measure (FIM) assesses functional independence across 18 items covering motor and cognitive domains. Each item is scored from 1 (total assistance required) to 7 (complete independence). Total score ranges from 18 to 126, with higher scores indicating greater independence in daily activities.
Baseline and 4 weeks
Change in Modified Rankin Scale (mRS) Score
Tidsramme: Baseline and 4 weeks
The modified Rankin Scale (mRS) measures the degree of disability or dependence in daily activities of participants who have had a stroke. Scores range from 0 (no symptoms) to 6 (death). Lower scores indicate better functional outcomes and greater independence.
Baseline and 4 weeks
Change in Hamilton Depression Scale (HAMD) Score
Tidsramme: Baseline and 4 weeks
The Hamilton Depression Scale (HAMD) assesses depressive symptoms across 17 items, including depressed mood, guilt, and insomnia. Total scores range from 0 to 42, with higher scores indicating more severe depression.
Baseline and 4 weeks
Change in Gait Speed
Tidsramme: Baseline and 4 weeks
Gait speed will be measured using the Gait and Balance Evaluation System during the 10-meter walk test. Participants will walk at their usual pace, and the average of three trials will be recorded in meters per second.
Baseline and 4 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. mai 2025

Primær fullføring (Faktiske)

1. november 2025

Studiet fullført (Antatt)

15. juli 2026

Datoer for studieregistrering

Først innsendt

13. juli 2026

Først innsendt som oppfylte QC-kriteriene

13. juli 2026

Først lagt ut (Faktiske)

16. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere